- Home
- PCRX
as 06-20-2025 3:40pm EST
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | TAMPA |
| Market Cap: | 1.2B | IPO Year: | 2011 |
| Target Price: | $29.89 | AVG Volume (30 days): | 546.7K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.16 - $29.61 | Next Earning Date: | 07-29-2025 |
| Revenue: | $702,772,000 | Revenue Growth: | 3.08% |
| Revenue Growth (this year): | 7.54% | Revenue Growth (next year): | 10.78% |
Stock Insider Trading Activity of Pacira BioSciences Inc. (PCRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WILLIAMS KRISTEN | PCRX | Chief Administrative Officer | Jun 3 '25 | Sell | $26.24 | 14,376 | $377,226.24 | 161,574 |
Latest Pacira BioSciences Inc. News
PCRX Breaking Stock News: Dive into PCRX Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
GlobeNewswire
3 days ago
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
GlobeNewswire
10 days ago
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
Argus Research
10 days ago
PCRX: Rating decreased to a HOLD
GlobeNewswire
16 days ago
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%
Argus Research
a month ago
PCRX: Raising target price to $29.00
GlobeNewswire
a month ago
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
Compare PCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.